Lars Jørgen Østergaard

Nelfinavir

Research output: Contribution to book/anthology/report/proceedingBook chapterResearchpeer-review

DOI

  • Suzanne M. Crowe, Alfred Hospital
  • ,
  • Lars Ostergaard
  • John Mills, Alfred Hospital

Nelfinavir mesylate is a selective, nonpeptidic inhibitor of the HIV protease, conferring moderately potent activity against HIV-1 and HIV-2. The drug was designed by protein structure-based techniques using iterative protein crystallographic analysis (Appelt et al., 1991). The mesylate salt was chosen for development based on favorable preformulation studies (Longer et al., 1995). Nelfinavir inhibits the HIV protease, resulting in the formation of immature and noninfectious particles by inhibiting the cleavage of the Gag- and Gag-Pol precursor polyproteins. It was developed by Agouron Pharmaceuticals and given the trade name Viracept.

Original languageEnglish
Title of host publicationKucers the Use of Antibiotics : A Clinical Review of Antibacterial, Antifungal, Antiparasitic, and Antiviral Drugs, Seventh Edition
Number of pages12
PublisherCRC Press
Publication year1 Jan 2017
Pages4075-4086
ISBN (print)9781498747950
ISBN (Electronic)9781498747967
DOIs
Publication statusPublished - 1 Jan 2017

See relations at Aarhus University Citationformats

ID: 207061707